The Combined Effect of Lower-Limb Multilevel Botulinum Toxin Type A and Comprehensive Rehabilitation on Mobility in Children With Cerebral Palsy: A Randomized Clinical Trial

Archives of Physical Medicine and Rehabilitation

Volumn 87, Issue 12, 2006, Pages 1551-1558

  Scholtes, Vanessa A ^a   Dallmeijer, Annet J ^a   Knol, Dirk L ^a   Speth, Lucianne A ^b   Maathuis, Carel G ^c   Jongerius, Peter H ^d   Becher, Jules G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Rehabilitation Foundation Linburg   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Botulinum toxin type A; Cerebral palsy; Clinical trials, randomized; Rehabilitation

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; CEREBRAL PALSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENERGY COST; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEALTH CARE; HUMAN; INTERVENTION STUDY; LEG; LEG MOVEMENT; LEG MUSCLE; MALE; MOTOR PERFORMANCE; NETHERLANDS; OUTCOME ASSESSMENT; PATIENT MOBILITY; PHYSIOTHERAPY; PRESCHOOL CHILD; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REHABILITATION CARE; REHABILITATION CENTER; REHABILITATION MEDICINE; SCHOOL CHILD; SCORING SYSTEM; SPASTICITY; THERAPY EFFECT; TREATMENT DURATION;

BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MOBILITY LIMITATION; NEUROMUSCULAR AGENTS; PHYSICAL THERAPY MODALITIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33751429746     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apmr.2006.08.342     Document Type: Article

References (28)

1. Wren T.A., Rethlefsen S., and Kay R.M. Prevalence of specific gait abnormalities in children with cerebral palsy: influence of cerebral palsy subtype, age, and previous surgery. J Pediatr Orthop 25 (2005) 79-83
2. In: Gage J.R. (Ed). The treatment of gait problems in cerebral palsy (2004), Mac Keith Pr, London
3. Gough M., Eve L.C., Robinson R.O., and Shortland A.P. Short-term outcome of multilevel surgical intervention in spastic diplegic cerebral palsy compared with the natural history. Dev Med Child Neurol 46 (2004) 91-97
4. Johnson D.C., Damiano D.L., and Abel M.F. The evolution of gait in childhood and adolescent cerebral palsy. J Pediatr Orthop 17 (1997) 392-396
5. Koman L.A., Mooney III J.F., Smith B., Goodman A., and Mulvaney T. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 13 (1993) 489-495
6. Molenaers G., Desloovere K., Eyssen M., Decat J., Jonkers I., and De Cock P. Botulinum toxin type A treatment of cerebral palsy: an integrated approach. Eur J Neurol 6 Suppl 4 (1999) 51-57
7. Leach J. Children undergoing treatment with botulinum toxin: the role of the physical therapist. Muscle Nerve Suppl 6 (1997) 194-207
8. Ubhi T., Bhakta B.B., Ives H.L., Allgar V., and Roussounis S.H. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 83 (2000) 481-487
9. Flett P.J., Stern L.M., Waddy H., Connell T.M., Seeger J.D., and Gibson S.K. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 35 (1999) 71-77
10. Baker R., Jasinski M., Maciag-Tymecka I., et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 44 (2002) 666-675
11. Kay R.M., Rethlefsen S.A., Fern-Buneo A., Wren T.A., and Skaggs D.L. Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy. J Bone Joint Surg Am 86 (2004) 2377-2384
12. Desloovere K., Molenaers G., Jonkers I., et al. A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol 8 Suppl 5 (2001) 75-87
13. Reddihough D.S., King J.A., Coleman G.J., et al. Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Dev Med Child Neurol 44 (2002) 820-827
14. Wissel J., Heinen F., Schenkel A., et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics 30 (1999) 120-124
15. Molenaers G., Eyssen M., Desloovere K., Jonkers I., and De Cock P. A multilevel approach to botulinum toxin type A treatment of the (ilio)psoas in spasticity in cerebral palsy. Eur J Neurol 6 Suppl 4 (1999) 59-62
16. World Health Organization. International classification of functioning, disability and health: ICF short version (2001), WHO, Geneva
17. Harlaar J., Redmeijer R.A., Tump P., Peters R., and Hautus E. The SYBAR system: integrated recording and display of video, EMG, and force plate data. Behav Res Methods Instrum Comput 32 (2000) 11-16
18. Kleissen R.F., Harlaar J., Bloo J.K., et al. Experimental use of multimedia movement analysis and telecommunication to support rehabilitation treatment planning. [abstract]. European Society of Movement Analysis for Adults and Children Annual Meeting (1998) Sept 24-26; Belfast (N Ireland).
19. Õunpuu S., Davis R.B., and DeLuca P.A. Joint kinetics: methods, interpretation and treatment decision-making in children with cerebral palsy and myelominengocele. Gait Posture 4 (1996) 62-78
20. In: Russell D. (Ed). Gross motor function measure (GMFM-66 & GMFM-88) user's manual (2002), Mac Keith Pr, London
21. Garby L., and Astrup A. The relationship between the respiratory quotient and the energy equivalent of oxygen during simultaneous glucose and lipid oxidation and lipogenesis. Acta Physiol Scand 129 (1987) 443-444
22. Wang H.Y., and Yang Y.H. Evaluating the responsiveness of 2 versions of the Gross Motor Function Measure for children with cerebral palsy. Arch Phys Med Rehabil 87 (2006) 51-56
23. Palisano R., Rosenbaum P., Walter S., Russell D., Wood E., and Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 39 (1997) 214-223
24. Peugh J.L., and Enders C.K. Using the SPSS mixed procedure to fit cross-sectional and longitudinal multilevel models. Educ Psychol Meas 65 (2005) 811-835
25. Boyd R.N., Graham J.E., Nattrass G.R., and Graham H.K. Medium-term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy. Eur J Neurol 6 Suppl 4 (1999) 37-45
26. Waters R.L., and Mulroy S. The energy expenditure of normal and pathologic gait. Gait Posture 9 (1999) 207-231
27. Hagberg B. Klinische Syndrome bei Cerebralparesen: eine umfassende neuropädiatrische Studie. Monatsschr Kinderheilkd 121 (1973) 259-264
28. Reimers J. The stability of the hip in children. A radiological study of the results of muscle surgery in cerebral palsy. Acta Orthop Scand Suppl 184 (1980) 1-100